Anti-IL-17A Monoclonal Antibody Pregnancy: B

Ixekizumab

Brand names: Taltz

Adult dose

Dose: 160 mg SC at week 0 (two 80 mg injections); then 80 mg every 2 weeks × 12 weeks; then 80 mg every 4 weeks

Route: subcutaneous injection

Frequency: Every 2 weeks (weeks 2–12); then every 4 weeks

Max: 80 mg every 2 weeks (initial); 80 mg every 4 weeks (maintenance)

Prefilled autoinjector (Eli Lilly pen); loading dose important for rapid onset; AS: 80 mg every 4 weeks (no loading)

Route: subcutaneous

Frequency: Every 4 weeks

Max: 80 mg

Concentration: 80 mg/mL autoinjector mg/ml

Plaque psoriasis ≥6 years: ≤25 kg: 40 mg; 25–50 kg: 80 mg; >50 kg: 160 mg at week 0 then weight-band dosing

Renal

No dose adjustment required

Hepatic

No dose adjustment required

UNCOVER trials: PASI 100 (complete clearance) in ~35% of patients at 12 weeks
Rapid onset: significant response by week 4
SPIRIT-H2H: head-to-head with adalimumab — superior for psoriasis, non-inferior for PsA

Live vaccines (CI)
CYP450 induction/inhibition at treatment initiation (normalisation of IL-17 levels)

Reference: BNFc; BNF 86; NICE TA442; UNCOVER trials. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Pathways